Peptide News Digest

Sapience Lucicebtide GBM ASCO 2026, Leerink/RBC TRIUMPH-1 Weekend, Corbus CRB-701 Nectin-4, Anglia Ruskin GLP-1 Cardiovascular Meta-Analysis, EASL 2026 MASH Preview

Sapience lucicebtide GBM ASCO, Leerink/RBC TRIUMPH-1 weekend commentary, Corbus CRB-701 Nectin-4, Anglia Ruskin 90K-patient GLP-1 CV meta-analysis, EASL preview.

10 stories · Covering clinical-trials, industry, research

Editor's Note

Saturday digest split across the TRIUMPH-1 weekend analyst-and-press cycle, two ASCO 2026 pre-meeting announcements that complete the peptide-oncology slate, and a fresh long-term cardiovascular meta-analysis. Leerink's David Risinger called Lilly's Thursday readout 'raising the bar for future novel obesity drug developers,' RBC Capital's Trung Huynh framed it as a 'clean win for Lilly,' and Dan Skovronsky's weekend CNBC commentary characterized 30% weight loss as 'an incredible number to see' — the post-readout coverage settling into broadly favorable territory with the dysesthesia signal (12.5% at 12 mg in TRIUMPH-1) the lingering open question. Sapience Therapeutics added its lucicebtide ASCO 2026 update Friday on the Phase 2 Window-of-Opportunity glioblastoma study (first-in-class C/EBPβ peptide antagonist, durable PFS and OS in 9 evaluable patients); Corbus Pharmaceuticals confirmed pre-ASCO data on CRB-701, a next-generation Nectin-4 antibody-drug conjugate, with the oral cervical cancer session May 29 and HNSCC poster May 30 plus FDA registrational-trial alignment for second-line HNSCC starting mid-2026. The Anglia Ruskin University meta-analysis published May 20 in Cardiovascular Diabetology - Endocrinology Reports synthesized data from 90,000+ patients across large international clinical trials documenting that GLP-1 receptor agonists significantly reduce heart attacks, strokes, heart failure, and premature death over the long term — the broadest evidence-base review to date. EASL 2026 Barcelona opens Wednesday May 27 with the multi-company MASH peptide slate (semaglutide ESSENCE liver safety subgroups, retatrutide MASLD Phase 3 status, survodutide SYNCHRONIZE-1, MetaVia vanoglipel + resmetirom). The pre-EASL momentum dovetails with the post-TRIUMPH-1 bariatric-surgery-comparison conversation: 45.3% of TRIUMPH-1 12 mg participants reached ≥30% weight loss, a level historically associated with bariatric outcomes — reframing the surgical referral conversation that anchors much of severe-obesity care.

Clinical Trials

Sapience Therapeutics Lucicebtide ASCO 2026 Phase 2 Update (May 22): First-in-Class C/EBPβ Peptide Antagonist Shows Durable PFS + OS in Window-of-Opportunity Newly Diagnosed Glioblastoma

Sapience Therapeutics announced May 22 positive Phase 2 clinical and pharmacodynamic data update from its lucicebtide (ST101) trial in glioblastoma ahead of the ASCO 2026 Annual Meeting (May 29-June 2 Chicago). The Phase 2 Window-of-Opportunity study evaluates lucicebtide alone and in combination with standard-of-care chemoradiation, with dosing both before and after surgical resection. Nine patients were evaluable for analysis; the maturing data show durable progression-free and overall-survival improvements with a well-tolerated safety profile. Lucicebtide is a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ) — a transcription factor that drives tumor aggressiveness, immune evasion, and stemness in glioblastoma. The 125-patient program across recurrent GBM monotherapy and newly diagnosed combination cohorts is the largest peptide-mechanism dataset in GBM to date. The Monday June 1 poster session details the efficacy, pharmacodynamics, and safety in newly-diagnosed patients.

#sapience-therapeutics #lucicebtide #st101 #c-ebp-beta #glioblastoma #asco-2026 #phase-2
Industry

Leerink + RBC + Lilly Weekend Commentary on TRIUMPH-1 (May 22-23): Risinger 'Raising the Bar,' Huynh 'Clean Win for Lilly,' Skovronsky '30% Weight Loss Is Incredible'

Day-after analyst commentary on Lilly's Thursday TRIUMPH-1 topline split favorably across major sell-side and management voices. Leerink Partners' David Risinger wrote that 'tolerability and substantial weight loss shown by retatrutide is raising the bar for future novel obesity drug developers,' a framing that lands at the higher end of the analyst spectrum after William Blair's tolerability-confined assessment Thursday. RBC Capital Markets' Trung Huynh characterized the readout as a 'clean win for [Lilly]' citing the clean safety profile plus best-in-class efficacy across all three doses. Dan Skovronsky, Lilly's chief scientific and product officer, told CNBC over the weekend that 30% weight loss in the BMI ≥35 extension is 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' The Saturday-Sunday news-cycle handling has settled into broadly favorable territory.

#retatrutide #triumph-1 #leerink #rbc-capital-markets #skovronsky #analyst-commentary #weekend-coverage
Clinical Trials

Corbus Pharmaceuticals CRB-701 ASCO 2026 Pre-Meeting Detail (May 22): Phase 1/2 Nectin-4 ADC in HNSCC + Cervical Cancer; Oral Cervical Session May 29, HNSCC Poster May 30, Mid-2026 Registrational Study Start in 2L HNSCC

Corbus Pharmaceuticals announced ASCO 2026 abstracts featuring updated clinical data from the Phase 1/2 study of CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting Nectin-4. The oral presentation in cervical cancer is scheduled for Thursday May 29 at 4:57 PM CDT; the head and neck squamous cell carcinoma (HNSCC) poster on Friday May 30 at 4:30 PM CDT. The data will include clinical response durability and HNSCC patient-subgroup analysis. Corbus reached broad alignment with the FDA on registrational-study designs in second-line HNSCC and cervical cancer, enabling potential accelerated approval based on objective response rate and full approval on overall survival. The company expects to initiate a registrational study for CRB-701 in second-line HNSCC mid-2026. CRB-701 targets the same Nectin-4 antigen as enfortumab vedotin (Padcev) and Bicycle Therapeutics' zelenectide pevedotin — the second-line HNSCC opportunity is the segment where the three programs will compete most directly.

#corbus-pharmaceuticals #crb-701 #nectin-4 #antibody-drug-conjugate #hnscc #cervical-cancer #asco-2026
Research

Anglia Ruskin Meta-Analysis (May 20, Cardiovascular Diabetology - Endocrinology Reports): 90,000+ Patient Review Confirms Long-Term GLP-1 Cardiovascular Protection Across MACE, Heart Failure, Premature Death

Researchers at Anglia Ruskin University published a systematic review and meta-analysis in Cardiovascular Diabetology - Endocrinology Reports on May 20 covering long-term cardiovascular outcomes for glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations. The review aggregated data from more than 90,000 participants across large international clinical trials. The headline finding: GLP-1 receptor agonists significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term in patients with established cardiovascular disease and high cardiovascular risk. The review extends the SELECT 20% MACE-reduction signal to the broader high-risk-CV population and joins the established cardiovascular-outcomes evidence base alongside the LEADER (liraglutide), SUSTAIN-6 (semaglutide), and STEP-HFpEF (semaglutide in heart failure) trial readouts. The Anglia Ruskin synthesis is the broadest evidence aggregation to date — directly relevant to the Medicare GLP-1 Bridge that begins July 1, 2026.

#anglia-ruskin #glp-1-cardiovascular #meta-analysis #long-term-outcomes #mace #heart-failure #cardiovascular-diabetology
Clinical Trials

TRIUMPH-1 Dysesthesia Signal Mechanism Discussion: 12.5% at 12 mg Tied to Glucagon-Receptor Activation, Dose-Dependent, Mild and Resolving in TRIUMPH-4 Follow-On

The TRIUMPH-1 dysesthesia signal (skin tingling, paresthesia-like sensations) that BMO Capital flagged Thursday merits a mechanistic look. The signal appeared in 12.5% of participants on retatrutide 12 mg in TRIUMPH-1, but was NOT reported in the Phase 2 retatrutide program. TRIUMPH-4 (December 2025 readout) recorded dysesthesia in approximately 20.9% of participants on the highest dose — most cases mild and resolving during ongoing treatment. The mechanistic explanation is tied to retatrutide's glucagon-receptor activation: glucagon signaling drives small-fiber sensory neuropathy patterns through downstream effects on c-AMP-mediated nociceptor sensitization. The pattern is dose-dependent (4 mg essentially no signal, 9 mg modest, 12 mg the peak). The clinical question is whether dysesthesia stays mild and reversible at commercial scale or whether a small fraction of patients develop persistent or more severe sensory disturbances. The signal is the differentiator from tirzepatide (no glucagon arm) and semaglutide (no glucagon, no GIP).

#retatrutide #triumph-1 #dysesthesia #glucagon-receptor #sensory-neuropathy #safety-signal
Industry

Pre-EASL 2026 Barcelona Peptide-MASH Slate (Opens Wednesday May 27): Semaglutide ESSENCE Liver Safety, Retatrutide MASLD Phase 3 Status, Survodutide SYNCHRONIZE-1, Vanoglipel + Resmetirom

The European Association for the Study of the Liver (EASL) Congress 2026 opens Wednesday May 27 in Barcelona with a heavy peptide-MASH slate. Novo Nordisk's ESSENCE Phase 3 program leads with liver-safety subgroup analyses (Japanese MASH cohort, women in menopause), building on the August 2025 FDA approval of semaglutide for MASH-with-fibrosis. Eli Lilly's retatrutide MASLD Phase 3 (NCT06859268) is enrolling on the 86% Phase 2 liver-fat reduction baseline. Boehringer Ingelheim survodutide SYNCHRONIZE-1 Phase 3 MASH data is expected late 2026 with positive results potentially establishing the GLP-1/glucagon dual agonist as standard of care alternative to semaglutide. MetaVia's vanoglipel (DA-1241, GPR119 agonist) Phase 2a + resmetirom combination work presented at ECO 2025 anchors the combination-MASH therapy thesis. The EASL plenaries plus the May 21 TRIUMPH-1 readout reframe MASH as a peptide-mechanism battleground rather than a single-drug indication.

#easl-2026 #mash #essence-trial #retatrutide-masld #survodutide #vanoglipel #barcelona
Industry

Retatrutide vs Bariatric Surgery — 45.3% of TRIUMPH-1 12 mg Participants Reached ≥30% Weight Loss, Reframing Surgical Referral Conversation

TRIUMPH-1 reported 45.3% of participants on the 12 mg dose reached ≥30% weight loss — historically the threshold associated with bariatric surgery outcomes (sleeve gastrectomy averages 25-30%, Roux-en-Y gastric bypass 30-35% at 1-2 years). The data point is the most consequential single statistic from the TRIUMPH-1 readout because it reframes the bariatric-referral conversation that anchors severe-obesity care. For patients with BMI 35-40 with comorbidities (the broadest bariatric-eligible population), pharmacological 30% weight loss closely approximates the surgical outcome without the irreversible anatomical changes, perioperative mortality (~0.1% gastric bypass), nutritional-deficiency monitoring requirements, or psychiatric adjustment patterns that follow bariatric procedures. Bariatric surgery centers' patient-referral volume began softening in 2024-2025 as Wegovy and Zepbound scaled; retatrutide's TRIUMPH-1 data accelerates that trend. The American Society for Metabolic and Bariatric Surgery (ASMBS) and the Obesity Society will likely revisit referral algorithms ahead of retatrutide's late-2027 launch.

#retatrutide #triumph-1 #bariatric-surgery #asmbs #surgical-referral #severe-obesity
Industry

ASCO 2026 Peptide-Oncology Calendar Roundup (May 29-June 2 Chicago): Specific Session Times for Bicycle, Avacta, Sapience, Corbus, BriaCell, BioVaxys, Crinetics

ASCO 2026 in Chicago opens Friday May 29 with the peptide-oncology calendar now fully fixed. Thursday May 29 4:57 PM CDT: Corbus CRB-701 Nectin-4 ADC oral session in cervical cancer. Friday May 30 4:30 PM CDT: Corbus CRB-701 HNSCC poster. Saturday May 30: BriaCell Bria-IMT three posters in metastatic breast cancer. Sunday May 31: Bicycle Therapeutics zelenectide pevedotin Phase 1 Duravelo-1 monotherapy update poster; Avacta AVA6000 FAP-Dox Phase 1a/1b in salivary gland cancers poster session. Monday June 1 8:30-8:36 AM CT: Bicycle Therapeutics Duravelo-2 oral abstract (Abstract 4516). Monday June 1: Sapience Therapeutics lucicebtide poster session for newly-diagnosed GBM. The peptide-oncology cohort is the largest single-meeting concentration of peptide-mechanism oncology data in recent ASCO history.

#asco-2026 #peptide-oncology #bicycle-therapeutics #avacta #sapience-therapeutics #corbus-pharmaceuticals #briacell
Clinical Trials

Retatrutide MASLD Phase 3 (NCT06859268) Enrollment Continues — 86% Phase 2 Liver-Fat Reduction Baseline; H1 2027 Topline Expected

Eli Lilly's retatrutide MASLD Phase 3 program (NCT06859268) continues enrollment across multiple international sites following the December 2025 Phase 2 readout that documented 86% mean liver-fat reduction at 48 weeks on 12 mg dosing. The Phase 3 trial enrolls adults with biopsy-confirmed MASH stages F2-F3 with primary endpoint at week 52 measuring MASH resolution without worsening of fibrosis. The 86% liver-fat reduction substantially exceeds the resmetirom 38-46% benchmark from the MAESTRO-NAFLD-1 reference cohort. Topline data is expected H1 2027; full results at AASLD or EASL 2027. The MASLD Phase 3 sits alongside TRIUMPH-3 (obesity + CVD) and TRIUMPH-OUTCOMES (10,000-patient cardiovascular outcomes trial reading 2027) as the second 2027 retatrutide catalyst. If positive, retatrutide files for MASH labeling alongside the obesity NDA — potentially within the same FDA submission window.

#retatrutide #masld #mash #phase-3 #nct06859268 #liver-fat-reduction #eli-lilly
Industry

Compounded GLP-1 Telehealth Saturday Market Sentiment: Ozari Health $86/Month Floor Holds, FDA 503B Comment Window Closes June 29

Six weeks ahead of the FDA's June 29 closing date for public comments on the April 30 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide, the compounded-GLP-1 telehealth segment has settled into a defensive pricing structure. Ozari Health's May 19 launch at $86/month compounded semaglutide and $120/month compounded tirzepatide established the floor; comparable platforms have held prices steady at $99-249/month rather than competing further on price. The Saturday market sentiment is split: bull case is that the FDA's final determination could grandfather existing 503A patients under a transition window, leaving cash-pay compounded GLP-1 viable through 2027; bear case is that the BSR Intelligence-documented 90% YoY drop in compounded semaglutide shipments accelerates as 503B compounding ends, with only the smallest-volume 503A pharmacies remaining. Patient migration toward branded Wegovy via Novo's Hims & Hers branded-distribution channel (125K shipments in six weeks) is the natural off-ramp.

#compounded-glp-1 #ozari-health #503b-comment #telehealth #june-29-deadline #market-sentiment